Data gathered: October 12
AI Stock Analysis - aTyr Pharma (ATYR)
Analysis generated October 11, 2025. Powered by Chat GPT.
aTyr Pharma, Inc. is a biopharmaceutical company primarily focused on developing treatments for rare diseases. The company leverages its proprietary drug discovery platform to deliver significant breakthroughs in the field of immunology. aTyr Pharma’s lead candidate includes EFHZ-601, targeted for various serious inflammatory and fibrotic diseases.
Stock Alerts - aTyr Pharma (ATYR)
 |
aTyr Pharma | October 10 Insider Alert: SCHIMMEL PAUL is buying shares |
|
aTyr Pharma | October 10 Price is up by 12.3% in the last 24h. |
|
aTyr Pharma | October 9 Price is down by -6.2% in the last 24h. |
|
aTyr Pharma | October 8 Price is up by 6.6% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for aTyr Pharma
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 5 | Sign up | Sign up | Sign up |
| Sentiment | 98 | Sign up | Sign up | Sign up |
| Webpage traffic | 60,000 | Sign up | Sign up | Sign up |
| Employee Rating | 82 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 1 | Sign up | Sign up | Sign up |
| Facebook Followers | 174 | Sign up | Sign up | Sign up |
| Instagram Followers | 118 | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 251 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 13,788 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,558 | Sign up | Sign up | Sign up |
| X Mentions | 18 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 74 | Sign up | Sign up | Sign up |
| Linkedin Employees | 83 | Sign up | Sign up | Sign up |
About aTyr Pharma
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
| Price | $1.06 |
| Target Price | Sign up |
| Volume | 21,620,000 |
| Market Cap | $104M |
| Year Range | $0.69 - $6.61 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitOctober 12 - GlobeNewswire |
|
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYROctober 12 - GlobeNewswire |
|
ATYR Investor Notice: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against aTyr Pharma, Inc.October 10 - GlobeNewswire |
|
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr PharmaOctober 10 - GlobeNewswire |
|
aTyr Pharma, Inc. (ATYR) Securities Class Action Deadline Alert: Shamis & Gentile, P.A. Alerts Investors of Important Lead Plaintiff Deadline of December 8, 2025October 10 - GlobeNewswire |
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of aTyr Pharma, Inc. Common Stock and Sets a Lead Plaintiff Deadline of December 8, 2025October 9 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 0 | 390,000 | -390,000 | -20M | -20M | -0.220 |
| Q1 '25 | 0 | 380,000 | -380,000 | -15M | -15M | -0.170 |
| Q4 '24 | 0 | 180,000 | -180,000 | -15M | -16M | -0.181 |
| Q3 '24 | 0 | 390,000 | -390,000 | -17M | -18M | -0.228 |
| Q2 '24 | 0 | 380,000 | -380,000 | -16M | -17M | -0.226 |
Insider Transactions View All
| SCHIMMEL PAUL filed to buy 1,413,023 shares at $0.9. October 9 '25 |
| SCHIMMEL PAUL filed to buy 1,095,024 shares at $0.9. October 9 '25 |
| Gross Jane A filed to buy 9,750 shares at $4. March 17 '25 |
| DENYES NANCY filed to sell 26,555 shares at $3.8. February 4 '25 |
| Broadfoot Jill Marie filed to sell 31,763 shares at $3.8. February 4 '25 |
Similar companies
Read more about aTyr Pharma (ATYR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of aTyr Pharma?
The Market Cap of aTyr Pharma is $104M.
What is the current stock price of aTyr Pharma?
Currently, the price of one share of aTyr Pharma stock is $1.06.
How can I analyze the ATYR stock price chart for investment decisions?
The ATYR stock price chart above provides a comprehensive visual representation of aTyr Pharma's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling aTyr Pharma shares. Our platform offers an up-to-date ATYR stock price chart, along with technical data analysis and alternative data insights.
Does ATYR offer dividends to its shareholders?
As of our latest update, aTyr Pharma (ATYR) does not offer dividends to its shareholders. Investors interested in aTyr Pharma should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of aTyr Pharma?
Some of the similar stocks of aTyr Pharma are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.
